Article Text

PDF
Practical guide for the comparison of two next-generation sequencing systems for solid tumour analysis in a universal healthcare system
  1. Perry Maxwell1,
  2. Seán O Hynes1,
  3. Marc Fuchs1,
  4. Stephanie Craig1,
  5. Claire McGready1,
  6. Fiona McLean1,2,
  7. Stephen McQuaid1,2,
  8. Jacqueline James1,2,
  9. Manuel Salto-Tellez1,2
  1. 1Northern Ireland Molecular Pathology Laboratory, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast, UK
  2. 2Tissue Pathology, Belfast Health and Social Care Trust, Belfast, UK
  1. Correspondence to Professor Manuel Salto-Tellez, Centre for Cancer Research and Cell Biology, Queen’s University Belfast, Belfast BT9 7AE, UK; m.salto-tellez{at}qub.ac.uk

Abstract

Aims Although there have been excellent reports in the literature of validating next-generation sequencing, comparisons between two systems are not often published due to cost and time. We set out to establish that targetable mutations could be reliably detected with different gene panels and different chemistries using a common bioinformatics pipeline for meaningful comparisons to be made.

Methods After running selected formalin-fixed, paraffin-embedded samples through QPCR, Sanger sequencing and the 50 gene hotspot v2 panel from Life Technologies to determine standard-of-care variants, we compared the Oncomine panel from Life Technologies performed on a Personal Genome Machine (PGM) and the eight-gene actionable panel from Qiagen performed on a MiSeq platform. We used a common bioinformatics program following the creation of respective VCF files.

Results Both panels were accurate to above 90%, the actionable panel workflow was easier to perform but the lowest effective starting DNA load was obtained on the Oncomine workflow at 4 ng. Such minimal DNA can help with samples where there is limited material such as those for lung cancer molecular studies. We also discuss gene panel content and propose that increasing the gene profile of a panel will not benefit clinical laboratories where standard-of-care testing is all that is required.

Conclusions Once recognised, it may be cost-effective for such laboratories to begin validation with an appropriate bioinformatics pipeline for targeted multigene hotspot molecular testing.

  • Molecular Pathology
  • Tumour Markers
  • Diagnosis

Statistics from Altmetric.com

Footnotes

  • Handling editor Runjan Chetty.

  • Contributors PM, SOH and MST designed the study, wrote and reviewed the manuscript. MF, CMG and FMcL performed experiments and analysis of data. SC performed statistical analysis. JJ and SMQ provided samples and reviewed the manuscript.

  • Funding SOH was supported by the Dr Richard Steevens Fellowship from the Health Service Executive, Ireland.

  • Competing interests None declared.

  • Patient consent Obtained.

  • Ethics approval Given by Northern Ireland Biobank.

  • Provenance and peer review Not commissioned; externally peer reviewed.

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.